Incredibly honored to get the mentorship award. Kelly Fitzgerald should really get the credit for the award. Truly thankful for having her as a mentee.

Patients with metastatic #kidneycancer have been living longer thanks to 20 years of U.S. FDA approvals, according to Dr. Chung-Han Lee (@ChungHanLee3) from Memorial Sloan Kettering Cancer Center & Dr. James Brugarolas (@JBrugarolas) from KidneyCancerProgram. #kcsm #gucsm #gerionc

ow.ly/UjhS50LaeZw

Awesome Memorial Sloan Kettering Cancer Center representation at #KCRS22

This #kidneycancer powerhouse on stage means serious business first thing. Brian Rini, MD Toni Choueiri, MD Sumanta Pal Laurence Albiges Martin Voss Rana McKay — Day 2 starts #KCRS22 KidneyCAN

Chung-Han Lee, MD, PhD, discussed the latest data supporting the use of #lenvatinib / #pembrolizumab as frontline therapy for patients with advanced clear cell renal cell carcinoma. #RCC #kcsm | Chung-Han Lee 李宗翰, MD/PhD Memorial Sloan Kettering Cancer Center

ow.ly/6MSF50KT3fV

Waking up at #ESMO22 ? Join us at 10:00 in the 4.B Brest Auditorium for a session on non-clear cell #kidneycancer . Exciting data/trials to be cited from Laurence Albiges Cristina Suárez Jeffrey Graham Daniel Heng Ulka Vaishampayan Chung-Han Lee 李宗翰, MD/PhD Toni Choueiri, MD Tom Powles Uromigos et al!

A reminder to everyone to get your abstracts submitted.

Looking forward to another exciting IKCS meeting. A great chance to see the pillars of the field of RCC talk about all the new research. I suspect there is going to be a lot to discuss with all of the recent press releases and annoucements.

The 2022 IKCS: North America will be here before you know it! Join us this fall in Austin, TX from November 4-5. Visit our website to register for #IKCSNA22 today and explore the program at a glance: bit.ly/3xemToY

During a Targeted Oncology case-based roundtable event, Chung-Han Lee, MD, PhD, discussed the approved frontline regimens for patients with advanced clear cell renal cell carcinoma. #rcc #kcsm Memorial Sloan Kettering Cancer Center Chung-Han Lee 李宗翰, MD/PhD

ow.ly/BjaE50K3wUt

Still quite a bit of room for improvement in the development of cell-free DNA assays for ccRCC. pubmed.ncbi.nlm.nih.gov/35797508/ Martin Voss
Ritesh Kotecha Any thoughts on how we can do better?

DoM's Chung-Han Lee 李宗翰, MD/PhD recently published results from a phase 2 trial in Journal of Clinical Oncology that showed cabozantinib/nivolumab was effective in the treatment of papillary, unclassified, or translocation-associated renal cell carcinoma. Read the study ⬇️ #Cancer
📖: ow.ly/oX7050JRFe6

Chung-Han Lee, MD, PhD, and Bradley A. McGregor, MD, discussed the case of a patient with recurrent metastatic renal cell carcinoma and that of a patient at risk of recurrence following resection. #rcc #kcsm Memorial Sloan Kettering Cancer Center Chung-Han Lee 李宗翰, MD/PhD Dana-Farber Lank Center for Genitourinary Oncology

ow.ly/GKAI50JJuTz

Experts share their thoughts on recent advances in treatment options for metastatic renal cell carcinoma and comment on emerging data in the field. #rccsm | David H Aggen, MD PhD Arnab Basu, MD, FACP Mehmet Asim Bilen,MD Chung-Han Lee 李宗翰, MD/PhD

cancernetwork.com/view/recap-saf…

Results from Durva+/-Olaparib in 1L platinum ineligible mUC published in JCO. No benefit in ITT, but prolonged PFS in HRRm patients. Worthy of further investigation. Tough trial to do, made possible by great international team. Memorial Sloan Kettering Cancer Center Journal of Clinical Oncology bit.ly/3NlFOUZ

Congratulations! Looking forward to welcoming Dr. Bange to MSK later this year! Memorial Sloan Kettering Cancer Center Erin Bange MD MSCE Michael Morris

For comparison, Checkmate9ER observed a 56% objective response rate in untreated clear cell RCC population receiving cabo/nivo. This non-clear cell #kidneycancer data from @chunghanlee3 & @motzerMD & colleagues in Journal of Clinical Oncology an important contribution. Nice job!

Great to see the successes of our Kidney Cancer YIA winners. Hoping that their work inspires a new generation of clinicians and scientists focused on #RCC Thank you Sumanta Pal for serving as the chair of the grant selection committee.

ICYMI: In this episode of #OncLiveOnAir , Chung-Han Lee 李宗翰, MD/PhD, of Memorial Sloan Kettering Cancer Center, highlights treatment developments in non–clear cell renal cell carcinoma, and emphasizes the need for precise classification of the histologic subsets of this disease. #rcc #kcsm ow.ly/B5u850JFeiI